p21-激活激酶家族在结直肠癌中的研究进展与展望  

Research progress and prospect of p21-activated kinase family in colorectal cancer

作　　者：潘荣天 张圆 吴霏 邹仁瑞 于韶荣[1] PAN Rongtian;ZHANG Yuan;WU Fei;ZOU Renrui;YU Shaorong(Department of Oncology,the Affiliated Cancer Hospital of Nanjing Medical University/Jiangsu Cancer Hospital/Jiangsu Institute of CancerResearch,Nanjing 210009,China)

机构地区：[1]南京医科大学附属肿瘤医院/江苏省肿瘤医院/江苏省肿瘤防治研究所肿瘤内科,江苏南京210009

出　　处：《中国肿瘤外科杂志》2024年第3期296-301,共6页Chinese Journal of Surgical Oncology

基　　金：国家自然科学基金面上项目(82172872,82373292)。

摘　　要：p21-激活激酶家族(PAKs)属于丝氨酸-苏氨酸蛋白激酶家族,已在多种细胞过程中展示出关键的调控作用。近年来,对于PAKs在结直肠癌中的研究取得了显著的进展,揭示了其在癌症发生和进展中的重要作用。文章论述PAKs在结直肠癌中的表达、调控机制以及对肿瘤生物学特性的影响,及其抑制剂的相关研究进展,为未来的研究和治疗方向提供启示。The p21-activated kinase family(PAKs),belonging to the serine/threonine protein kinase family,plays crucial regulatory roles in various cellular processes.In recent years,significant progress has been made in the study of PAKs in colorectal cancer,highlighting their pivotal roles in cancer development and progression.This review summarizes the latest research advancements,focusing on the expression,regulatory mechanisms,and the biological functions of PAKs in colorectal cancer.Additionally,it highlights the progress in research on PAKs inhibitors and provides insights for future directions in research and treatment.

关 键 词：p21-激活激酶家族 结直肠癌 PAK家族抑制剂 

分 类 号：R735.34[医药卫生—肿瘤]